Iradimed (NASDAQ:IRMD) Rating Reiterated by Roth Mkm

Iradimed (NASDAQ:IRMD)‘s stock had its “buy” rating reissued by equities research analysts at Roth Mkm in a report released on Monday, Benzinga reports. They currently have a $65.00 price target on the medical equipment provider’s stock. Roth Mkm’s target price would indicate a potential upside of 55.13% from the company’s previous close.

Separately, Singular Research reiterated a “buy” rating on shares of Iradimed in a report on Monday, April 1st.

Iradimed Price Performance

Shares of IRMD opened at $41.90 on Monday. The firm has a 50 day simple moving average of $42.98 and a two-hundred day simple moving average of $43.02. The company has a market cap of $530.45 million, a P/E ratio of 30.81 and a beta of 0.82. Iradimed has a one year low of $36.12 and a one year high of $51.04.

Iradimed (NASDAQ:IRMD) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.01). The company had revenue of $17.45 million for the quarter. Iradimed had a return on equity of 24.62% and a net margin of 26.22%. On average, analysts expect that Iradimed will post 1.35 earnings per share for the current fiscal year.

Institutional Trading of Iradimed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Copeland Capital Management LLC acquired a new stake in Iradimed in the third quarter valued at $30,000. Gladius Capital Management LP acquired a new stake in Iradimed in the third quarter valued at $36,000. AJOVista LLC acquired a new stake in Iradimed in the fourth quarter valued at $66,000. Hsbc Holdings PLC acquired a new stake in Iradimed in the third quarter valued at $251,000. Finally, Summit Global Investments increased its holdings in Iradimed by 22.5% in the fourth quarter. Summit Global Investments now owns 7,088 shares of the medical equipment provider’s stock valued at $336,000 after purchasing an additional 1,300 shares during the period. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.